Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program

Oppenheimer Raises Price Target Following Five Prime Therapeutics' (FPRX) Announced Licensing Agreement with BMY

October 19, 2015 6:42 AM EDT

Oppenheimer reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX), and raised the price target to $48.00 (from $45.00), following the company's Oct. 15th announcement of a licensing agreement for FPA008 with BMY. FPRX will receive $350M cash upfront and is eligible for an additional $1.39B in development/regulatory... More

Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY

October 15, 2015 4:06 PM EDT

Leerink Partners reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX) following an announced exclusive $1.74Bn license and collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) for the development and commercialization of FPRXs CSF1R antibody... More